Biotech Breakthrough: NanoViricides Advances Dual-Action Drug Into Trials ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Small Caps Daily.
 The company’s lead drug, NV-387, is advancing into Phase II clinical trials—with the potential to transform both cancer care and antiviral treatment. Here’s why this matters to investors: -
Cancer Recurrence Prevention: Viral infections like COVID-19, Influenza, RSV, and measles can “wake up” dormant cancer cells, fueling deadly metastasis. NV-387’s unique antiviral anti-inflammatory properties—including reduced IL-6 cytokine levels—may stop this process before it starts. -
Best-in-Class Data: Preclinical studies show NV-387 provides superior lung protection and dramatically lowers inflammation versus leading antivirals (Tamiflu, Rapivab, Xofluza). -
Massive Market Potential: By addressing viral infections and cancer recurrence prevention, NV-387 could unlock multi-billion-dollar opportunities across oncology and infectious disease markets. -
Platform Advantage: NanoViricides’ exclusive nanoviricide™ technology is designed to block viral escape—even against new and evolving variants. With COVID-19 now endemic, seasonal influenza surging, and cancer recurrence remaining one of medicine’s greatest challenges, NV-387 is positioned at the crossroads of oncology and virology. This is more than a clinical milestone—it could be a medical revolution. As NNVC moves deeper into human trials, investors now have the chance to get in front of what may become a first-in-class therapy protecting millions of patients worldwide. 👉 [Learn More About NNVC and NV-387’s Breakthrough Potential] |
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $5,500 and was received/will be received from Interactive Offers. This communication should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) by Small Caps Daily and Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 09/14/2025. Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.
|
|
